Testing for Homologous Recombination Deficiency in Ovarian & Other Tumor Types

Time: 3:15 pm
day: Day One Track B PM

Details:

  • Myriad developed the MyChoice CDx test to identify patients with homologous recombination deficient (HRD) tumors
  • Many other HRD tests show limited agreement with the clinically validated companion diagnostic test
  • MyChoice CDx is approved for ovarian cancer, but may have applications in breast and prostate cancer

Speakers: